Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Share-based Compensation: 2023-2025

Historic Share-based Compensation for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $1.2 million.

  • Compass Therapeutics' Share-based Compensation fell 43.68% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year increase of 10.84%. This contributed to the annual value of $8.6 million for FY2024, which is 39.87% up from last year.
  • Per Compass Therapeutics' latest filing, its Share-based Compensation stood at $1.2 million for Q3 2025, which was down 55.64% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, Compass Therapeutics' Share-based Compensation ranged from a high of $2.8 million in Q2 2025 and a low of $1.2 million during Q3 2025.
  • Moreover, its 3-year median value for Share-based Compensation was $2.0 million (2024), whereas its average is $1.9 million.
  • In the last 5 years, Compass Therapeutics' Share-based Compensation spiked by 58.09% in 2024 and then plummeted by 43.68% in 2025.
  • Over the past 3 years, Compass Therapeutics' Share-based Compensation (Quarterly) stood at $1.6 million in 2023, then soared by 39.87% to $2.2 million in 2024, then tumbled by 43.68% to $1.2 million in 2025.
  • Its Share-based Compensation stands at $1.2 million for Q3 2025, versus $2.8 million for Q2 2025 and $2.5 million for Q1 2025.